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ABSTRACT 
A Targeting Strategy to Overcome Tumor 
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Historically, drug as a free form has been directly used in cancer treatment. 
However, while the anticancer drugs can be distributed throughout the 
whole body, it is very toxic and causes many side effects to normal tissues. 
To overcome this problem, many nano-technologies have been applied for 
an effective delivery of anticancer drugs to the targeting cancer cells. In this 
study, we developed polymerized metabolic precursor (pMPs) to improve 
tumor-targeting abilities. Furthermore, the pMPs is designed to overcome 
the intrinsic limitations causing from the limited amount of cellular 
receptors and the heterogeneity of tumor cells. The pMPs are based on 
metabolic glycoengineering and click chemistry. Triacetylated N-
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azidoacetyl-D-mannosamine (Ac3ManNAz) is conjugated to the PAMAM 
[G4] dendrimer backbone and the compound generates azide groups on the 
surface of tumor tissue specifically. Regardless of tumor cell types, pMPs 
create a more uniform cancer cells with artificial glycans on their surface. 
With the enhanced permeation and retention (EPR) effect followed by 
metabolic glycoengineering, the pMPs generate ‘receptor-like’ chemical 
reporters to produce a homogeneous cancer cell surface in the tumor tissue. 
Then, they can be labeled by ADIBO-Cy5.5 via copper-free click chemistry 
in vivo condition.  
 
Keywords: Polymerized Metabolic Precursors (pMPs), Tumor 
Heterogeneity, Metabolic Glycoengineering, Click Chemistry, Optical 
Imaging  
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Figure 1. (a) Schematic illustration of the targeting strategy to overcome 
tumor heterogeneity using polymerized metabolic precursors (pMPs). (b) 
Chemical structure of pMPs. 
 
Figure 2. Synthetic scheme of pMPs. 
 
Figure 3. TLC analysis    
 
Figure 4. 1H-NMR spectra of (a) PAMAM [G4], (b) Ac3ManNAz, and (c) 
PAMAM [G4]-Ac3ManNAz. 300 MHz NMR, solvent; DMSO-d6. 
 
Figure 5. Matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) data of (a) PAMAM [G4] and (b) 
PAMAM [G4]-Ac3ManNAz. 
 
Figure 6. Viability of tumor cells treated with pMPs for 2 days. 
 
Figure 7. Azide group generation on cell surface after treatment of pMPs. 
(a) Visualization of azide groups on the surface of U87 tumor cells after 
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treatment of pMPs. (b) Coomassie staining and wetern blot analysis of U87 
tumor cells treated with pMPs. (c) Visualization of azide groups on the 
surface of human dermal fibroblasts (HDFs, normal cells) after treatment of 
pMPs.  
 
Figure 8. Generation of azide groups by pMPs in various tumor cells. (a) 
The binding of click molecules and biological ligands to tumor cells. 
ADIBO-Cy5.5, cRGD-PEG-Cy5.5, Cetuximab-Cy5.5, and Folate-PEG-
Cy5.5 were visualized in red, yellow, green, and blue fluorescence (pseudo 
colors).  (b) Flow cytometry analysis of tumor cells after treatment of 
pMPs and ADIBO-Cy5.5. ADIBO-Cy5.5 was added to tumor cells treated 
with pMPs (50 μM) for 2 days. 
 
Figure 9. Intratumoral injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. Coomassie staining and wetern blot analysis of 
Ac3ManNAz or pMPs treated tumor tissues. 
 
Figure 10. Biodistribution of pMPs in tumor-bearing mice. (a) Whole body 
images of mice after intravenous injection of Cy5.5-labeled pMPs. (b) 
Fluorescence intensities of tumor tissues from (a). (c) Ex vivo fluorescence 
images of major organs and tumor from 72 h post-injection of pMPs. (d) 
Fluorescence intensities of major organs and tumor tissue from (c). 
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Figure 11. Intravenous injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. (a) Coomassie staining and wetern blot analysis of 
tumor tissues after intravenous injection of saline, free Ac3ManNaz, or 
pMPs. (b) Whole body images of mice after intraveneous injection of 
ADIBO-Cy5.5, pretreated with pMPs. (c) Ex vivo fluorescence images of 
tumors from each group 24 h postinjection of ADIBO-Cy5.5. (d) 
Fluorescence intensities of tumor tissues from (c). 
 
Figure 12. Intravenous injection of saline, free Ac3ManNAz, and pMPs and 
metabolic glycoengineering on tumor tissue in vivo. Histological staining of 
major organs and tumor tissues after intravenous injection of saline (left 
panel), free Ac3ManNAz (middle panel), and pMPs (right panel). 
 
Figure 13. Fluorescence images of tumor tissues after intravenous injection 
of ADIBO-Cy5.5 to tumor-bearing mice pretreated with saline (top panel), 
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1. INTRODUCTION 
 
Metabolic glycoengineering is a useful biological technique pioneered by 
Carolyn Bertozzi’s group1. It utilizes an intrinsic glycan metabolism of cells 
to introduce unnatural glycans with various chemical groups2. When 
rationally designed metabolic precursors are treated, cells applicate them as 
building blocks for glycan metabolism. These precursors are inserted within 
the structure of glycans3. Until today, lots of papers studied about a wide 
range of applications in this technique from precise analysis of glycans at 
molecular level to spatiotemporal imaging in vivo4. Particularly, combined 
with click chemistry, biorthogonal chemical groups can be easily introduced 
to glycans by this technique and they enable click reactions on the glycans 
in cells or bodies as well as in ex vivo condition for various purposes5. 
For more than one century, several kinds of nanoparticles have shown 
promising results in imaging and drug delivery6. However, their tumor-
targeting ability is still limited, and there are many obstacles to improve 
their efficacy7. In particular, current active-targeting method using 
biological ligands has intrinsic limitations, because the amount of receptors 
on tumor cells is limited and the binding of nanoparticles can be saturated8. 
In addition, the heterogeneity of tumor cells makes the situation more 
complicated since numerous subpopulations of tumor cells express different 
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kinds and amounts of receptors9. Heterogeneity can be observed within 
cancers of same tissue as well as in different types of cancer. In this point of 
view, we expect that chemical groups can be introduced onto tumor tissue 
containing heterogeneous tumor cells. If so, they would be used as artificial 
active-targeting moieties for the delivery of nanoparticles and provide 
alternative ways to overcome tumor heterogeneity. Importantly, a targeted 
delivery of metabolite and tumor cell-specific introduction of chemical 
groups will be much useful for tumor imaging or drug delivery.  
Herein, in order to overcome tumor heterogeneity, we developed 
polymerized metabolic precursors for biorthogonal targeting strategy in 
living body (Figure 1a).  Polymerized metabolic precursors (pMPs) were 
synthesized by conjugation of triacetylated N-azidoacetyl-D-mannosamine 
(Ac3ManNAz), the precursor for azide generation, to the succinic acid 
terminated generation 4 poly (amido amine) (PAMAM [G4])-dendrimer 
backbone (Figure 1b). The pMPs are intravenously injected to tumor-
bearing mice. This injection results in site-specific generation of azide 
groups on tumor tissue due to the EPR effect. Under the acidic tumor 
microenvironment, it can be hydrolyzed into free form of Ac3ManNAz 
which can introduce azide groups onto tumor cells surface by metabolic 
glycoengineering. Our approach generates ‘receptor-like’ chemical groups 
on the surface of target cells by pMPs alone. The advantage of this method 
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over biological receptors is that the small azide groups can expressed on the 
cell surface in large quantities regardless of the types or subpopulations of 
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Figure 1. (a) Schematic illustration of the targeting strategy to overcome 
tumor heterogeneity using polymerized metabolic precursors (pMPs). (b) 
Chemical structure of pMPs. 
 
  




Succinamic acid terminated generation 4 poly (amido amine) (PAMAM 
[G4]) dendrimer was purchased as 5 wt% in water from Dendritech, Inc. 
(Midland, MI, USA). The water was removed by lyophilization before any 
further experiments. Triacetylated N-azidoacetyl-D-mannosamine 
(Ac3ManNAz) was achieved from FutureChem (Seoul, Korea). 1-ehtyl-3-
(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), 4-
(Dimethylamino) pyridine (DMAP), Dimethyl sulfoxide (DMSO) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Cy5.5-NHS was 
acquired from GE Healthcare Life Sciences (Piscataway, NJ, USA). 
ADIBO-Cy5.5 was purchased from FutureChem (Seoul, Korea).  
 
2.2 Conjugation of PAMAM [G4] Dendrimer-Ac3ManNAz  
Esterification of PAMAM [G4] was carried out according to Steglich 
esterification mechanism. PAMAM [G4] dendrimers were dissolved in 1 ml 
DMSO in the presence of EDC and DMAP as catalysts at 1 to 1.2 ratios. 
Then, 3 molar equivalents of triacetylated mannosamine (Ac3ManNAz) with 
PAMAM [G4] dendrimers were added to the DMSO solution containing 
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PAMAM [G4] dendrimers and catalysts. The reactants were stirred at room 
temperature for 72 hours and were dialyzed in DMSO for another 72 hours 
using a cellulose membrane (MWCO 3500: Spectrum Laboratories, TX, 
USA) at room temperature to remove unreacted EDC, DMAP and 
Ac3ManNAz. After dialysis, the Ac3ManNAz conjugated PAMAM [G4] 
dendrimers were obtained by lyophilization.  
 
2.3 Characterization of PAMAM [G4] Dendrimer-
Ac3ManNAz (Polymerized Metabolic Precursors, pMPs) 
Thin Layered Chromatography (TLC) aluminum plates (Silica gel 60 
F254, Merck kGaA, Darmstadt, Germany) were used to monitor the 
progress of the reaction. Reactants and products dissolved in DMSO (0.1 
g/ml) were spotted onto a start line on one side of the TLC plates at different 
time points (1, 2, 3, 5 days). In TLC chambers, chloroform/methanol (2:1, 
v/v) was used as a developing eluent for the plates. After evaporation of 
developing solvents, chromatographic spots of samples were exposed under 
uv lamp. 1H NMR analysis was performed by Bruker Advance-300 MHz 
spectrometer in DMSO-d6 solution at room temperature (MA, USA). 1H 
NMR peaks of pMPs were as follows: 2.02 (s; H of acetyl groups from 
Ac3ManNAz, 9H), 2.49-2.53 (s; H of CH2-CH2 from PAMAM, 4H), 3.06 
(s; H of CH2-CH2 from PAMAM in between -NH, 4H), 5.04-5.24 (m; H of 
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Ac3ManNAz, 1H), 5.99 (s; H of Ac3ManNAz, 1H), 7.88 (s; H of NH from 
PAMAM, 3H), 8.50-8.53 (d; H of NH from Ac3ManNAz, 1H) (Figure 4c). 
Mass spectra was measured by matrix-assisted laser desorption ionization 
time-of-flight mass spectrometer (MALDI-TOF MS; PAMAM m/z 
calculated: 20615, found: 19277, pMPs m/z calculated: 45447, found: 
38599) (Figure 5). The conjugated amount of Ac3ManNAz was determined 
by high performance liquid chromatography (HPLC).  
 
2.4 Synthesis of Cy5.5-labeled pMPs 
The pMPs were labeled with Cy5.5 to trace their movement by 
fluorescence. Cy5.5-NHS was dissolved in deionized distilled water and 
added to the water solution containing PAMAM [G4] dendrimer. The 
mixture was reacted in the dark at room temperature for 72 hours. Then, free 
Cy5.5-NHS were removed by dialysis against deionized distilled water 
using a cellulose membrane (MWCO 3500) for 3 days. The final product 
was lyophilized to give Cy5.5-labeled PAMAM [G4]. After all, 
Ac3ManNAz was conjugated to Cy5.5-labeled PAMAM [G4] to give Cy5.5-





 ８  
2.5 Cell culture  
U87 (Human glioblastoma) cells, HDF (Human dermal fibroblasts) cells, 
MCF-7 (Human mammary carcinoma) cells, human breast adenocarcinoma 
cells (MDA-MB-468 and MDA-MB-436), KB (Human epidermoid 
carcinoma) cells, and A549 (Human lung adenocarcinoma) cells were 
purchased from ATCC (Manassas, VA, USA). Those cell lines were 
maintained in RPMI1640 (Welgene, Daegu, Korea) containing 10% fetal 
bovine serum (FBS; Welgene, Daegu, Korea), 100 µg/ml streptomycin, and 
100 U/ml penicillin (Welgene, Daegu, Korea) in a humidified 5% CO2 
atmosphere at 37℃.  
 
2.6 Cell viability Assay 
U87 cells were seeded on 96-well plates (5x103 cells/well) and incubated 
for one day. To measure the cytotoxicity of pMPs, the cells were treated 
with Ac3ManNAz, PAMAM [G4], or pMPs with various concentration of 
Ac3ManNAz: 6.25, 12.5, 25, 50, 100 uM. After incubation for two days, the 
cells were washed twice with DPBS (pH 7.4) and 20 uL of MTT in serum-
free RPMI1640 media (0.5 mg/mL) was added to each well. After further 
incubation for 2 h at 37 ºC, the media was removed and cells were dissolved 
in 200 uL of DMSO. Then, the absorbance of each well was measured at 
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572 nm using a microplate reader (VERSAmaxTM, Molecular Devices 
Corp., Sunnyvale, CA).  
 
2.7 Western blot analysis of cells 
U87 cells were seeded onto 100 x 20 mm cell culture plates at a density 
of 2 x 106 cells per plate in 12 mL of media with Ac3ManNAz (50 µM) or 
pMPs (50 µM Ac3ManNAz). After 2 days of incubation, the cells were 
washed twice with DPBS (pH 7.4) and harvested from the plates using a cell 
scraper. The cells were pelleted by centrifugation at 1500 rpm for 5 min, and 
the cell pellets were re-suspended in 500 µl of lysis buffer (1 % SDS, 100 
mM Tris∙HCl, pH 7.4) containing protease inhibitor cocktail (Complete, 
EDTA-free, Roche, NSW, Australia). They were lysed with a probe-type 
sonifier at 4 ºC. Sonicated lysates were incubated at 4 ºC for 30 min to 
further solubilized proteins, and insoluble debris was removed by 
centrifugation for 10 min at 3,000 x g. Final soluble protein concentrations 
were determined by bicinchoninic acid (BCA) protein assay (Pierce, 
Rockford, IL, USA) to be 5 mg/ml. Then, 20 µl of the lysate was incubated 
with 2 µl of phosphine-PEG3-biotin (5 mM in DPBS) (Pierce, Rockford, IL, 
USA) for 6 hours at 37 ºC. SDS-PAGE loading buffer was added to each 
sample and the samples were heated at 95 ºC, before loading onto 10% SPS-
PAGE gel. Proteins were transferred to Hybond P membrane (Amercham, St. 
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Albans, UK), and the membrane was blocked with 5 % bovine serum 
albumin (BSA) in TBST (50 mM Tris∙HCl, 150 mM NaCl, 0.1 % Tween20, 
pH 7.4) for 2 hours. Then, the membrane was incubated with streptavidin-
HRP (diluted 1:2000 in TBST) (Pierce, Rockford, IL, USA) overnight at 4 
ºC. The membrane was rinsed three times with TBST and developed by 
ECL Western Blotting Substrate (Pierce, Rockford, IL, USA). 
 
2.8 Cellular imaging to determine the generated azide groups 
U87 and HDF cells were seeded onto 35 mm glass-bottom dishes at a 
density of 2 x 104 cells in 2 mL of media with no sugar, Ac3ManNAz (50 
µM), or pMPs (50 µM Ac3ManNAz). After incubation for two days, the 
cells were washed twice with DPBS (pH 7.4) and incubated for 1 hour with 
ADIBO-Cy5.5 (20 µM, final concentration) (Future Chem, Seoul, Korea) in 
37 ºC incubator. They were rinsed with DPBS (pH 7.4) and fixed with a 
fixative containing formaldehyde-glutaraldehyde for 15 min at room 
temperature. Then, the cells were washed with DPBS (pH 7.4) again and 
stained with DAPI (Invitrogen, Carlsbad, CA, USA) to label nuclei. All 
cellular images were obtained by a confocal laser microscope (Leica TCS 
SP8, Leica Microsystems GmbH, Germany) with 405 diode (405 nm) and 
He-Ne (633nm) lasers.  
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2.9 Cellular imaging of the bindings of click molecules or 
biological ligands to various tumor cells 
ADIBO-Cy5.5 (FutureChem, Seoul, Korea) was used as purchased with 
no further purification. In order to prepare cRGD-PEG-Cy5.5, similar amide 
coupling of c(RGDyK) with (t-Boc)-protected PEG-NHS (Mw 2,000), 
followed by TFA cleavage was carried out. The cRGD-PEG conjugate (8 
mg; 2 µmol) was incubated with Cy5.5-NHS (10 µmol) in 500 µL of 
phosphate buffer (10 mM, pH 7.4) for 2 h in the dark at room temperature. 
Final product was purified by HPLC. Cetuximab-Cy5.5 was synthesized by 
the reaction of anti-EGFR monoclonal antibody, Cetuximab (3.3 nmol), and 
Cy5.5-NHS (40 nmol) in phosphate buffer (0.1 M, pH 8.5). After 2 h 
reaction, the mixture was purified using PD-10 column to remove unreacted 
Cy5.5. To prepare folate-PEG-Cy5.5, folic acid (10 mg) was added into 60 
mL of ethylenediamine (EDA) and stirred in the dark for 3 h at room 
temperature. After precipitation in acetone twice, the precipitate was 
dissolved in water and filtrated to remove the insoluble substance. Then, this 
folate-EDA (20 mg, 24 µmol) was incubated with (t-Boc)-NH2-PEG-NHS 
(Mw 2,000) in 2.5 mL DMSO for 2 h, and treated by TFA for deprotection 
of t-Boc. The folate-PEG conjugates (10 mg; 4 µmol) was incubated with 
Cy5.5-NHS (10 µmol) in 500 µL phosphate buffer (10 mM, pH 7.4) for 2 h 
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in the dark at room temperature. The final product, folate-PEG-Cy5.5 
conjugate was purified by HPLC.  
All cells were seeded onto 35 mm glass-bottom dishes at a density of 3 x 
104 cells in 2 mL of growth media with no sugar or pMPs (50 µM 
Ac3ManNAz). After 2 days of incubation, the cells were washed twice with 
DPBS (pH 7.4), and incubated with ADIBO-Cy5.5 (20 µM, final 
concentration) for 30 min at 37 °C for cellular imaging. The same method 
was applied to all cell lines: U87, MCF-7, MDA-MB-468, MDA-MB-436, 
KB, and A549 cells. 
For the comparative study using traditional biological binding molecules, 
all cells were seeded onto 35 mm glass-bottom dishes at a density of 3 x 104 
cells in 2 mL of growth media and grown to reach 60-80 % confluence. The 
cells were washed twice with DPBS (pH 7.4), and incubated with cRGD-
PEG-Cy5.5 (0.2 µM, final concentration), Cetuximab-Cy5.5 (0.1 µM, final 
concentration), or Folate-PEG-Cy5.5 (0.2 µM, final concentration) for 30 
min at 37 °C for cellular imaging. Fluorescence images were observed using 
confocal laser microscope (Leica TCS SP8, Leica Microsystems GmbH, 
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2.10 Flow cytometry analysis 
U87 cells were seeded onto 6-well plates at a density of 2 x 104 cells per 
well in 2 mL of media with no sugar or pMPs (50 µM Ac3ManNAz) treated 
with ADIBO-Cy5.5, as described previously. The cells were lifted with 
DPBS containing 2 % FBS (flow cytometry buffer) and washed twice in 
FACS buffer (1 mM EDTA). Twenty thousand cells per sample were 
performed by flow cytometry (BD FACSVerse, BD Biosciences, San Jose, 
CA, USA), and subsequent data analysis was analyzed using FlowJo 
software. 
 
2.11 In vivo/ex vivo imaging 
All experiments with live animals were performed in compliance with the 
laws and institutional guidelines of Korea Institute of Science and 
Technology (KIST) and approved by institutional committees. For in vivo 
and ex vivo experiments, U87 tumor cells (1.0 x 107 cells) were 
subcutaneously planted on flank of 5-week-old male athymic nude mice (20 
g, Orient, Gyeonggi-do, Korea). When the tumor reached about 100 mm2, 
the experiments were conducted. Cy5.5-labeled pMPs (40 mg 
Ac3ManNAz/kg) was injected intravenously once. The mice model was 
observed over 3 days to display in vivo biodistribution of pMPs. Near-
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infrared fluorescence (NIRF) images were observed using the IVIS Lumina 
K Series III in vivo imaging system (Perkin Elmer, Waltham, MA, USA). 
For analysis of expression of azide groups on tumor tissue, free 
Ac3ManNAz or pMPs (40 mg Ac3ManNAz/kg) were injected daily for 2 
days. After that, ADIBO-Cy5.5 (10 mM, 40 µL) was injected (n=3 per each 
experimental group). All the injections were done intravenously. The 
biodistribution and time-dependent tumor accumulation profiles were non-
invasively imaged by IVIS Lumina K Series III in vivo imaging system 
(Perkin Elmer, Waltham, MA, USA). All data were calculated by the region 
of interest (ROI) function of the IVIS molecular imaging software.  
The major organs and tumors were dissected from mice 72 hours post-
injection of Cy5.5-labeled pMPs. For analysis of expression of azide groups 
on tumor tissue, the tumors were dissected from mice 24 hours post-
injection of free Ac3ManNAz or pMPs (40 mg Ac3ManNAz). Ex vivo 
images were also obtained with a IVIS Lumina K Series III in vivo imaging 
system (Perkin Elmer, Waltham, MA, USA), and the fluorescence signal 
intensity at the ROI using IVIS molecular imaging software.  
 
2.12 Histological imaging 
For histological evaluation, the dissected tumor tissues were fixed in 4 % 
(v/v) buffered formalin solution, and embedded in optimum cutting 
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temperature (OCT) compound (Sakura, Tokyo, Japan) on dry ice. Sections 
were cut on a cryostat with 6 μm in thickness and picked up on slides with 
poly-D-lysine, dried at 45 °C under protection from light. Fluorescence of 
tumor tissue sections was observed (excitation: 673 nm, emission: 692 nm) 
by IX81-ZDC focus drift compensating microscope (Olympus, Tokyo, 
Japan). 
 
2.13 Western blot analysis of tumor tissues 
Preparation of U87 tumor-bearing mice models and intravenous injection 
of Ac3ManNAz (40 mg/kg) or pMPs (40 mg Ac3ManNAz/kg) were 
performed by the same method. 48 hours post-injection of Ac3ManNAz or 
pMPs, the major organs and tumors were dissected and transferred into 1 ml 
of lysis buffer (1 % SDS, 100 mM Tris∙HCl, pH 7.4) containing protease 
inhibitor cocktail (Complete, EDTA-free, Roche, NSW, Australia) and 
homogenized. The lysates were incubated at 4 ºC for 30 min, and insoluble 
debris was removed by centrifugation for 10 min at 3,000 x g. Using BCA 
protein assay kit, total soluble protein concentrations were measured. 
Staudinger reaction with phosphine-PEG3-biotin, SDS-PAGE, and western 
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2.14 Immunohistochemical analysis 
The dissected tumor tissues were retrieved from U87 tumor-bearing mice, 
and fixed in 4 % (v/v) buffered formalin solution. The tissues were 
dehydrated with a graded ethanol series, and embedded in paraffin. The 
paraffin tissues were sliced in 4 μm wide slices, and immunohistochemical 
staining was performed using phosphine-PEG3-biotin and streptavidin-HRP 
followed by the standard methods. The paraffin slices were dried and then 
mounted with Permount SP15-100 Toluene Solution (Fisher Scientific, NJ, 
USA) mounting media. The samples were observed by a light microscope 
(BX51, Olympus, Tokyo, Japan), and were photographed using a digital 
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3. RESULTS AND DISCUSSION 
 
3.1 Characterization of pMPs 
Poly (amido amine) (PAMAM) [G4] dendrimer is used as a basic 
structure of the polymerized metabolic precursors (pMPs) with a well-
established characteristics, and Ac3ManNAz is used for metabolic 
glycoengineering of sialic acids (Figure 1b). Ac3ManNAz can act as a 
building block in cell metabolism, since it can easily produce unnatural 
sialic acid, the most abundant glycan on tumor cell surface10. Conjugation of 
PAMAM [G4] dendrimer and Ac3ManNAz is completed by Steglich 
esterification mechanism (Figure 2). A completion of the reaction was 
determined by TLC (Figure 3). The free PAMAM [G4] dendrimer was 
stayed on the start line because of its high polarity, and pMPs was mobilized 
at maximum height on 3 days after the reaction. There is no further 
movement of pMPs after 3 days of reaction; the reaction time was fixed as 3 
days. After the reaction, free Ac3ManNAz, free PAMAM, and pMPs are 
analyzed by 1H NMR (Figure 4). By comparison of the reactants and 
product, 1H NMR peaks promised that the reaction was successfully 
completed. In addition, MALDI-TOF determined molecular weight of free 
PAMAM (m/z calculated: 20615, found: 19277) and that of pMPs (m/z 
calculated: 45447, found: 38599) (Figure 5). The Ac3ManNAz conjugation 
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efficiency was confirmed as 82.58 % using HPLC. Moreover, the size of 
pMPs was 3.88 ± 0.51 nm in aqueous condition as determined by dynamic 
light scattering (DLS). It promise that pMPs is small enough to freely move 
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Figure 4. 1H-NMR spectra of (a) PAMAM [G4], (b) Ac3ManNAz, and (c) 
PAMAM [G4]-Ac3ManNAz. 300 MHz NMR, solvent; DMSO-d6. 
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Figure 5. Matrix-assisted laser desorption/ionization-time of flight mass 
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3.2 In vitro studies of pMPs 
In vitro studies establish the generation of azide groups on the surface of 
tumor cells. First, azide group generation on cell surface was determined by 
cellular imaging and western blot analysis. Free Ac3ManNAz or pMPs was 
added to U87 tumor cells, and azide groups were determined by binding 
with ADIBO-Cy5.5 (red fluorescence). After treatment of free Ac3ManNAz 
or pMPs for 2 days, the viability of U87 cells was above 90% showing no 
significant cytotoxicity (Figure 6). ADIBO is chosen as a bioorthogonal 
chemical group functionalized with its high reactivity to azide groups via 
copper-free click chemistry5b. After treatment with ADIBO-Cy5.5, a higher 
fluorescence intensity of Cy5.5 was observed in both free Ac3ManNAz and 
pMPs treated U87 tumor cells than in untreated cells (Figure 7a). The 
microscopic images indicated that artificially introduced azide groups on the 
tumor cell surface were successfully generated by free Ac3ManNAz and 
pMPs, and effectively targeted by ADIBO-Cy5.5. Unlike U87 cells, a 
normal cell line, such as HDF (human dermal fibroblast) cell, did not show 
a strong signal of fluorescence after treatment of free Ac3ManNAz or pMPs 
(Figure 7c). As mentioned earlier, the surface of tumor cell is especially rich 
in sialic acid. Therefore, even though Ac3ManNAz can easily make 
unnatural sialic acid through metabolic glycoengineering, HDF normal cells 
cannot be visualized as U87 tumor cells. Western blot analysis using 
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phosphine-PEG3-biotin and streptavidin-HRP likewise demonstrated the 
generation of azide groups on tumor cells after the treatment of free 
Ac3ManNAz or pMPs (Figure 7b)11. Coomassie staining verifies that the 
total loading amount of proteins for each group of cell lysates is similar.  
 The heterogeneity of tumor cells complicates the circumstances for various 
subpopulations of tumor cells expressing different types and amounts of 
receptors9. Tumor is increasingly acknowledged as a combination of many 
disorders, each with varying causes, prognoses, and appropriate treatments. 
This diversity is recognizable not only across different types of tumor, but 
also within tumors of the same tissue. It is now known that cancer cells 
within the same tumor mass are heterogeneous in many aspects, including 
morphology or phenotypic expression, exhibition of inherent or acquired 
drug resistance, and capacity for initiating new tumor growth9. The 
heterogeneity and complexity of tumor is a huge obstruction of present drug 
delivery systems. However, our strategy can generate ‘receptor-like’ 
chemical groups on heterogeneous tumor cells by metabolic 
glycoengineering and overcome the limitation of current drug delivery 
systems. To demonstrate, a comparative study using representative click 
molecules and biological ligands was performed on various cell types: U87, 
MCF-7, MDA-MB-468, MDA-M-436, KB, and A549. ADIBO was used as 
a click molecule, and biological ligands such as cRGD (peptide), Cetuximab 
  
 ２５  
(antibody), and folate were used, in order to label the azide group with 
Cy5.5 dye. The biological receptors for these ligands are known to be 
expressed in specific tumor cells, and each ligand labeled with Cy5.5 was 
bound to the targeted cells only as expected. However, after treatment of 
pMPs, all cell types (U87, MCF-7, MDA-MB-468, MDA-M-436, KB, and 
A549) were positively visualized on cellular imaging with ADIBO-Cy5.5 
(Figure 8a). The azide groups were generated on all cell types by metabolic 
glycoengineering, so they could bind with ADIBO-Cy5.5. The fluorescence 
intensity of these cells was quantified using flow cytometry analysis. 
Compared to the control cells with no treatment, the tumor cells treated with 
pMPs indicated a higher intensity (Figure 8b). These results show that azide 
groups are successfully generated from pMPs and formed on the surface of 
various cell lines. These results demonstrate that polymerized metabolic 
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Figure 7. Azide group generation on cell surface after treatment of pPMs. 
(a) Visualization of azide groups on the surface of U87 tumor cells after 
treatment of pMPs. (b) Coomassie staining and wetern blot analysis of U87 
tumor cells treated with pMPs. (c) Visualization of azide groups on the 
surface of human dermal fibroblasts (HDFs, normal cells) after treatment of 
pMPs.  
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Figure 8. Generation of azide groups by pMPs in various tumor cells. (a) 
The binding of click molecules and biological ligands to tumor cells. 
ADIBO-Cy5.5, cRGD-PEG-Cy5.5, Cetuximab-Cy5.5, and Folate-PEG-
Cy5.5 were visualized in red, yellow, green, and blue fluorescence (pseudo 
colors).  (b) Flow cytometry analysis of tumor cells after treatment of 
pMPs and ADIBO-Cy5.5. ADIBO-Cy5.5 was added to tumor cells treated 
with pMPs (50 μM) for 2 days. 
  
 ２９  
3.3 In vivo studies of pMPs 
For in vivo studies, balb/c nude mice models bearing xenograft U87 
tumor on one side of flank are prepared. In vivo experiments start when the 
tumor size reached about 100 mm3. First, targetable glycans, unnatural sialic 
acids with azide groups, are artificially generated in target cancer cells by an 
intratumoral injection of the precursor, pMPs. Free Ac3ManNAz or pMPs 
were administered to each tumor model by intratumoral injection once a day 
for 3 days while saline was injected to the control mice model. The 
coomassie blue staining and western blot analysis of tumor tissues showed 
that the unnatural sialic acid with azide groups similarly with the cellular 
conditions (Figure 9). 
The biodistribution of pMPs is evaluated by time-dependent whole body 
imaging and ex vivo fluorescence analysis12. Whole body distribution was 
measured using a non-invasive IVIS Lumina K Series III in vivo imaging 
system in live animals. Cy5.5 labeled pMPs was intravenously injected once 
for fluorescent tracking. The images showed a slow excretion of pMPs over 
time (Figure 10a). Fluorescence intensities of tumor tissues from the images 
were quantified and plotted with a mild decreasing curve (Figure 10b). Total 
photon count in tumor site is distinctively higher in Cy5.5-labeled pMPs 
than free Cy5.5. Based on the EPR effect12, pMPs reached to the tumor 
more specifically and remained there using its characteristics of polymer. 
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Therefore, compared to small molecules like free Cy5.5 dye, pMPs bring a 
slower excretion through the whole body, especially from the tumor. In ex 
vivo fluorescence analysis of major organs and tumors, tumor tissue from 
mice pretreated with pMPs exhibited higher fluorescence intensity than 
other major organ tissues, except for the liver (Figure 10c and 10d). We 
expected that a strong signal from the liver was caused as a part of 
enterohepatic circulation.  
For intravenous injection of pMPs and metabolic glycoengineering on 
tumor tissue in vivo, western blot analysis, whole body and ex vivo 
fluorescence imaging were evaluated. Three different models of mice were 
prepared with saline, free Ac3ManNAz, or pMPs by intravenous injection. 
After 2 days of injection, ADIBO-Cy5.5 was also injected through tail vein 
to label the azide groups on cell surface by click chemistry. The tumors were 
collected and analyzed after all the injections. Compared to saline and free 
Ac3ManNAz, the tumor tissue from mice injected with pMPs revealed a 
strong band in western blot analysis (Figure 11a). The result showed that a 
large number of azide groups were generated on tumor tissue from pMPs by 
metabolic glycoengineering. The azide groups can be specifically generated 
in tumor tissue by pMPs because of its tumor-targeting ability via the EPR 
effect. The tumor tissue from mice pretreated with pMPs shows significantly 
more intense fluorescence in vivo images than tumor tissues pretreated with 
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saline or free Ac3ManNAz (Figure 11b). Even though the number of azide 
groups generated by Ac3ManNAz and pMPs were similar in vitro, the in 
vivo images were different because free Ac3ManNAz is a small molecule 
that has no tumor-targeting ability. The tumors from each group were 
dissected after 24 hours from injection of ADIBO-Cy5.5. They were 
analyzed by ex vivo fluorescence images and tumor tissue from mice 
pretreated with pMPs showed distinctively higher intensity of fluorescence 
than tumors from other group pretreated with saline or free Ac3ManNAz 
(Figure 11c and 11d). Furthermore, immuohistological staining supports the 
metabolic glycoengineering of pMPs. The dark brown spots which show the 
expression of azide group are intense in tumor tissue, compared to other 
organ tissues (Figure 12). The immunohistology also demonstrates that 
metabolic glycoengineering can specifically occur on the tumor tissue after 
intravenous injection of pMPs. A large number of azide groups can be 
successfully generated on tumor tissue in vivo. More specifically, 
histological evaluation proves the generation of azide group from pMPs by 
the accumulation of ADIBO-Cy5.5 in tumor tissue (Figure 13). It was 
significantly higher in pMPs pretreated mice group than other groups with 













Figure 9. Intratumoral injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. Coomassie staining and wetern blot analysis of 













Figure 10. Biodistribution of pMPs in tumor-bearing mice. (a) Whole body 
images of mice after intravenous injection of Cy5.5-labeled pMPs. (b) 
Fluorescence intensities of tumor tissues from (a). (c) Ex vivo fluorescence 
images of major organs and tumor from 72 h post-injection of pMPs. (d) 
Fluorescence intensities of major organs and tumor tissue from (c). 
 
  







Figure 11. Intravenous injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. (a) Coomassie staining and wetern blot analysis of 
tumor tissues after intravenous injection of saline, free Ac3ManNaz, or 
pMPs. (b) Whole body images of mice after intraveneous injection of 
ADIBO-Cy5.5, pretreated with pMPs. (c) Ex vivo fluorescence images of 
tumors from each group 24 h postinjection of ADIBO-Cy5.5. (d) 
Fluorescence intensities of tumor tissues from (c). 
  





Figure 12. Intravenous injection of saline, free Ac3ManNAz, and pMPs and 
metabolic glycoengineering on tumor tissue in vivo. Histological staining of 
major organs and tumor tissues after intravenous injection of saline (left 
panel), free Ac3ManNAz (middle panel), and pMPs (right panel). 
 
  








Figure 13. Fluorescence images of tumor tissues after intravenous injection 
of ADIBO-Cy5.5 to tumor-bearing mice pretreated with saline (top panel), 
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4. CONCLUSION 
  
In this study, we have designed polymerized metabolic precursors (pMPs) 
to overcome tumor heterogeneity via metabolic glycoengineering and click 
chemistry. PAMAM [G4] dendrimers are conjugated with Ac3ManNAz to 
produce pMPs. The intravenously injected pMPs reach to the tumor cell 
specifically by EPR effect and successfully produce azide groups on the 
surface of tumor cells. In particular, an expression of azide groups enables a 
generation of ‘receptor-like’ chemical reporters from pMPs itself. 
Furthermore, by using AIBO-Cy5.5, these azide reporters in the tumor tissue 
can be labeled via copper-free click chemistry in vivo condition. Thus, the 
tumor can be specifically visualized by optical imaging system. Our results 
suggest a new targeting strategy which can overcome tumor heterogeneity 
using site-specific metabolic glycoengineering and copper-free click 
chemistry. Since the whole procedure is conducted of intravenous injections 
only, allowing it to be applied to tumor diagnosis and therapy even when the 
location of the tumor tissue is not well defined. Our strategy significantly 
demonstrates that it may have a great potential for further biomedical 
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요약문 
 
기존에 암 치료는 항암제를 단독으로 직접 투여하는 방식을 
사용하였다. 하지만 이러한 방법은 암 세포 뿐만 아니라 정상 
세포까지 독성을 야기하는 등 다양한 부작용을 나타내었다. 
이러한 문제점을 해결하기 위해서 항암제를 표적 암 세포에 
전달하는 다양한 나노기술이 개발되어왔다. 본 연구에서는 
고분자화 대사 전구체를 이용하여 암 표적화 능력을 향상 시키는 
방법에 대한 것이다. 또한, 암 세포가 갖는 고유 수용체의 양적 
제한에서 비롯된 표적 능력의 한계 및 암 이질성을 극복할 수 
있는 방법에 대한 것이다. 이 방법은 대사 당쇄 조작과 무동 클릭 
화학을 이용하였다. PAMAM [G4] 덴드리머와 Triacetylated 
N-azidoacetyl-D-mannosamine (Ac3ManNAz)의 화학적 
결합을 이용하여 암 조직에 특이적으로 인공 표적 수용체인 
azide 기를 도입시키는 방법이며, 이 방법을 이용하면 이질성을 
갖는 암 세포들을 단일화된 표현 형질로 바꿀 수 있다. 또한 
이렇게 도입된 인공 표적 수용체를 표적으로 하는 클릭 화학을 
이용하면 암 표적화 능력을 향상 시킬 수 있다. 본 연구에서 개발 
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된 고분자화 대사 전구체를 이용한 암 표적화 능력 향상 방법을 
이용하면 이질성을 갖는 암의 종류에 상관없이 표적 능력을 높일 
수 있을 것으로 예상된다.  
 
주요 어: 고분자화 대사 전구체, 종양 이질성, 물질 대사 당공학, 
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ABSTRACT 
A Targeting Strategy to Overcome Tumor 
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Seoul National University 
 
Historically, drug as a free form has been directly used in cancer treatment. 
However, while the anticancer drugs can be distributed throughout the 
whole body, it is very toxic and causes many side effects to normal tissues. 
To overcome this problem, many nano-technologies have been applied for 
an effective delivery of anticancer drugs to the targeting cancer cells. In this 
study, we developed polymerized metabolic precursor (pMPs) to improve 
tumor-targeting abilities. Furthermore, the pMPs is designed to overcome 
the intrinsic limitations causing from the limited amount of cellular 
receptors and the heterogeneity of tumor cells. The pMPs are based on 
metabolic glycoengineering and click chemistry. Triacetylated N-
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azidoacetyl-D-mannosamine (Ac3ManNAz) is conjugated to the PAMAM 
[G4] dendrimer backbone and the compound generates azide groups on the 
surface of tumor tissue specifically. Regardless of tumor cell types, pMPs 
create a more uniform cancer cells with artificial glycans on their surface. 
With the enhanced permeation and retention (EPR) effect followed by 
metabolic glycoengineering, the pMPs generate ‘receptor-like’ chemical 
reporters to produce a homogeneous cancer cell surface in the tumor tissue. 
Then, they can be labeled by ADIBO-Cy5.5 via copper-free click chemistry 
in vivo condition.  
 
Keywords: Polymerized Metabolic Precursors (pMPs), Tumor 
Heterogeneity, Metabolic Glycoengineering, Click Chemistry, Optical 
Imaging  
 
Student number: 2013-20621 
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tumors from each group 24 h postinjection of ADIBO-Cy5.5. (d) 
Fluorescence intensities of tumor tissues from (c). 
 
Figure 12. Intravenous injection of saline, free Ac3ManNAz, and pMPs and 
metabolic glycoengineering on tumor tissue in vivo. Histological staining of 
major organs and tumor tissues after intravenous injection of saline (left 
panel), free Ac3ManNAz (middle panel), and pMPs (right panel). 
 
Figure 13. Fluorescence images of tumor tissues after intravenous injection 
of ADIBO-Cy5.5 to tumor-bearing mice pretreated with saline (top panel), 
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1. INTRODUCTION 
 
Metabolic glycoengineering is a useful biological technique pioneered by 
Carolyn Bertozzi’s group1. It utilizes an intrinsic glycan metabolism of cells 
to introduce unnatural glycans with various chemical groups2. When 
rationally designed metabolic precursors are treated, cells applicate them as 
building blocks for glycan metabolism. These precursors are inserted within 
the structure of glycans3. Until today, lots of papers studied about a wide 
range of applications in this technique from precise analysis of glycans at 
molecular level to spatiotemporal imaging in vivo4. Particularly, combined 
with click chemistry, biorthogonal chemical groups can be easily introduced 
to glycans by this technique and they enable click reactions on the glycans 
in cells or bodies as well as in ex vivo condition for various purposes5. 
For more than one century, several kinds of nanoparticles have shown 
promising results in imaging and drug delivery6. However, their tumor-
targeting ability is still limited, and there are many obstacles to improve 
their efficacy7. In particular, current active-targeting method using 
biological ligands has intrinsic limitations, because the amount of receptors 
on tumor cells is limited and the binding of nanoparticles can be saturated8. 
In addition, the heterogeneity of tumor cells makes the situation more 
complicated since numerous subpopulations of tumor cells express different 
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kinds and amounts of receptors9. Heterogeneity can be observed within 
cancers of same tissue as well as in different types of cancer. In this point of 
view, we expect that chemical groups can be introduced onto tumor tissue 
containing heterogeneous tumor cells. If so, they would be used as artificial 
active-targeting moieties for the delivery of nanoparticles and provide 
alternative ways to overcome tumor heterogeneity. Importantly, a targeted 
delivery of metabolite and tumor cell-specific introduction of chemical 
groups will be much useful for tumor imaging or drug delivery.  
Herein, in order to overcome tumor heterogeneity, we developed 
polymerized metabolic precursors for biorthogonal targeting strategy in 
living body (Figure 1a).  Polymerized metabolic precursors (pMPs) were 
synthesized by conjugation of triacetylated N-azidoacetyl-D-mannosamine 
(Ac3ManNAz), the precursor for azide generation, to the succinic acid 
terminated generation 4 poly (amido amine) (PAMAM [G4])-dendrimer 
backbone (Figure 1b). The pMPs are intravenously injected to tumor-
bearing mice. This injection results in site-specific generation of azide 
groups on tumor tissue due to the EPR effect. Under the acidic tumor 
microenvironment, it can be hydrolyzed into free form of Ac3ManNAz 
which can introduce azide groups onto tumor cells surface by metabolic 
glycoengineering. Our approach generates ‘receptor-like’ chemical groups 
on the surface of target cells by pMPs alone. The advantage of this method 
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over biological receptors is that the small azide groups can expressed on the 
cell surface in large quantities regardless of the types or subpopulations of 
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Figure 1. (a) Schematic illustration of the targeting strategy to overcome 
tumor heterogeneity using polymerized metabolic precursors (pMPs). (b) 
Chemical structure of pMPs. 
 
  




Succinamic acid terminated generation 4 poly (amido amine) (PAMAM 
[G4]) dendrimer was purchased as 5 wt% in water from Dendritech, Inc. 
(Midland, MI, USA). The water was removed by lyophilization before any 
further experiments. Triacetylated N-azidoacetyl-D-mannosamine 
(Ac3ManNAz) was achieved from FutureChem (Seoul, Korea). 1-ehtyl-3-
(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), 4-
(Dimethylamino) pyridine (DMAP), Dimethyl sulfoxide (DMSO) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Cy5.5-NHS was 
acquired from GE Healthcare Life Sciences (Piscataway, NJ, USA). 
ADIBO-Cy5.5 was purchased from FutureChem (Seoul, Korea).  
 
2.2 Conjugation of PAMAM [G4] Dendrimer-Ac3ManNAz  
Esterification of PAMAM [G4] was carried out according to Steglich 
esterification mechanism. PAMAM [G4] dendrimers were dissolved in 1 ml 
DMSO in the presence of EDC and DMAP as catalysts at 1 to 1.2 ratios. 
Then, 3 molar equivalents of triacetylated mannosamine (Ac3ManNAz) with 
PAMAM [G4] dendrimers were added to the DMSO solution containing 
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PAMAM [G4] dendrimers and catalysts. The reactants were stirred at room 
temperature for 72 hours and were dialyzed in DMSO for another 72 hours 
using a cellulose membrane (MWCO 3500: Spectrum Laboratories, TX, 
USA) at room temperature to remove unreacted EDC, DMAP and 
Ac3ManNAz. After dialysis, the Ac3ManNAz conjugated PAMAM [G4] 
dendrimers were obtained by lyophilization.  
 
2.3 Characterization of PAMAM [G4] Dendrimer-
Ac3ManNAz (Polymerized Metabolic Precursors, pMPs) 
Thin Layered Chromatography (TLC) aluminum plates (Silica gel 60 
F254, Merck kGaA, Darmstadt, Germany) were used to monitor the 
progress of the reaction. Reactants and products dissolved in DMSO (0.1 
g/ml) were spotted onto a start line on one side of the TLC plates at different 
time points (1, 2, 3, 5 days). In TLC chambers, chloroform/methanol (2:1, 
v/v) was used as a developing eluent for the plates. After evaporation of 
developing solvents, chromatographic spots of samples were exposed under 
uv lamp. 1H NMR analysis was performed by Bruker Advance-300 MHz 
spectrometer in DMSO-d6 solution at room temperature (MA, USA). 1H 
NMR peaks of pMPs were as follows: 2.02 (s; H of acetyl groups from 
Ac3ManNAz, 9H), 2.49-2.53 (s; H of CH2-CH2 from PAMAM, 4H), 3.06 
(s; H of CH2-CH2 from PAMAM in between -NH, 4H), 5.04-5.24 (m; H of 
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Ac3ManNAz, 1H), 5.99 (s; H of Ac3ManNAz, 1H), 7.88 (s; H of NH from 
PAMAM, 3H), 8.50-8.53 (d; H of NH from Ac3ManNAz, 1H) (Figure 4c). 
Mass spectra was measured by matrix-assisted laser desorption ionization 
time-of-flight mass spectrometer (MALDI-TOF MS; PAMAM m/z 
calculated: 20615, found: 19277, pMPs m/z calculated: 45447, found: 
38599) (Figure 5). The conjugated amount of Ac3ManNAz was determined 
by high performance liquid chromatography (HPLC).  
 
2.4 Synthesis of Cy5.5-labeled pMPs 
The pMPs were labeled with Cy5.5 to trace their movement by 
fluorescence. Cy5.5-NHS was dissolved in deionized distilled water and 
added to the water solution containing PAMAM [G4] dendrimer. The 
mixture was reacted in the dark at room temperature for 72 hours. Then, free 
Cy5.5-NHS were removed by dialysis against deionized distilled water 
using a cellulose membrane (MWCO 3500) for 3 days. The final product 
was lyophilized to give Cy5.5-labeled PAMAM [G4]. After all, 
Ac3ManNAz was conjugated to Cy5.5-labeled PAMAM [G4] to give Cy5.5-
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2.5 Cell culture  
U87 (Human glioblastoma) cells, HDF (Human dermal fibroblasts) cells, 
MCF-7 (Human mammary carcinoma) cells, human breast adenocarcinoma 
cells (MDA-MB-468 and MDA-MB-436), KB (Human epidermoid 
carcinoma) cells, and A549 (Human lung adenocarcinoma) cells were 
purchased from ATCC (Manassas, VA, USA). Those cell lines were 
maintained in RPMI1640 (Welgene, Daegu, Korea) containing 10% fetal 
bovine serum (FBS; Welgene, Daegu, Korea), 100 µg/ml streptomycin, and 
100 U/ml penicillin (Welgene, Daegu, Korea) in a humidified 5% CO2 
atmosphere at 37℃.  
 
2.6 Cell viability Assay 
U87 cells were seeded on 96-well plates (5x103 cells/well) and incubated 
for one day. To measure the cytotoxicity of pMPs, the cells were treated 
with Ac3ManNAz, PAMAM [G4], or pMPs with various concentration of 
Ac3ManNAz: 6.25, 12.5, 25, 50, 100 uM. After incubation for two days, the 
cells were washed twice with DPBS (pH 7.4) and 20 uL of MTT in serum-
free RPMI1640 media (0.5 mg/mL) was added to each well. After further 
incubation for 2 h at 37 ºC, the media was removed and cells were dissolved 
in 200 uL of DMSO. Then, the absorbance of each well was measured at 
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572 nm using a microplate reader (VERSAmaxTM, Molecular Devices 
Corp., Sunnyvale, CA).  
 
2.7 Western blot analysis of cells 
U87 cells were seeded onto 100 x 20 mm cell culture plates at a density 
of 2 x 106 cells per plate in 12 mL of media with Ac3ManNAz (50 µM) or 
pMPs (50 µM Ac3ManNAz). After 2 days of incubation, the cells were 
washed twice with DPBS (pH 7.4) and harvested from the plates using a cell 
scraper. The cells were pelleted by centrifugation at 1500 rpm for 5 min, and 
the cell pellets were re-suspended in 500 µl of lysis buffer (1 % SDS, 100 
mM Tris∙HCl, pH 7.4) containing protease inhibitor cocktail (Complete, 
EDTA-free, Roche, NSW, Australia). They were lysed with a probe-type 
sonifier at 4 ºC. Sonicated lysates were incubated at 4 ºC for 30 min to 
further solubilized proteins, and insoluble debris was removed by 
centrifugation for 10 min at 3,000 x g. Final soluble protein concentrations 
were determined by bicinchoninic acid (BCA) protein assay (Pierce, 
Rockford, IL, USA) to be 5 mg/ml. Then, 20 µl of the lysate was incubated 
with 2 µl of phosphine-PEG3-biotin (5 mM in DPBS) (Pierce, Rockford, IL, 
USA) for 6 hours at 37 ºC. SDS-PAGE loading buffer was added to each 
sample and the samples were heated at 95 ºC, before loading onto 10% SPS-
PAGE gel. Proteins were transferred to Hybond P membrane (Amercham, St. 
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Albans, UK), and the membrane was blocked with 5 % bovine serum 
albumin (BSA) in TBST (50 mM Tris∙HCl, 150 mM NaCl, 0.1 % Tween20, 
pH 7.4) for 2 hours. Then, the membrane was incubated with streptavidin-
HRP (diluted 1:2000 in TBST) (Pierce, Rockford, IL, USA) overnight at 4 
ºC. The membrane was rinsed three times with TBST and developed by 
ECL Western Blotting Substrate (Pierce, Rockford, IL, USA). 
 
2.8 Cellular imaging to determine the generated azide groups 
U87 and HDF cells were seeded onto 35 mm glass-bottom dishes at a 
density of 2 x 104 cells in 2 mL of media with no sugar, Ac3ManNAz (50 
µM), or pMPs (50 µM Ac3ManNAz). After incubation for two days, the 
cells were washed twice with DPBS (pH 7.4) and incubated for 1 hour with 
ADIBO-Cy5.5 (20 µM, final concentration) (Future Chem, Seoul, Korea) in 
37 ºC incubator. They were rinsed with DPBS (pH 7.4) and fixed with a 
fixative containing formaldehyde-glutaraldehyde for 15 min at room 
temperature. Then, the cells were washed with DPBS (pH 7.4) again and 
stained with DAPI (Invitrogen, Carlsbad, CA, USA) to label nuclei. All 
cellular images were obtained by a confocal laser microscope (Leica TCS 
SP8, Leica Microsystems GmbH, Germany) with 405 diode (405 nm) and 
He-Ne (633nm) lasers.  
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2.9 Cellular imaging of the bindings of click molecules or 
biological ligands to various tumor cells 
ADIBO-Cy5.5 (FutureChem, Seoul, Korea) was used as purchased with 
no further purification. In order to prepare cRGD-PEG-Cy5.5, similar amide 
coupling of c(RGDyK) with (t-Boc)-protected PEG-NHS (Mw 2,000), 
followed by TFA cleavage was carried out. The cRGD-PEG conjugate (8 
mg; 2 µmol) was incubated with Cy5.5-NHS (10 µmol) in 500 µL of 
phosphate buffer (10 mM, pH 7.4) for 2 h in the dark at room temperature. 
Final product was purified by HPLC. Cetuximab-Cy5.5 was synthesized by 
the reaction of anti-EGFR monoclonal antibody, Cetuximab (3.3 nmol), and 
Cy5.5-NHS (40 nmol) in phosphate buffer (0.1 M, pH 8.5). After 2 h 
reaction, the mixture was purified using PD-10 column to remove unreacted 
Cy5.5. To prepare folate-PEG-Cy5.5, folic acid (10 mg) was added into 60 
mL of ethylenediamine (EDA) and stirred in the dark for 3 h at room 
temperature. After precipitation in acetone twice, the precipitate was 
dissolved in water and filtrated to remove the insoluble substance. Then, this 
folate-EDA (20 mg, 24 µmol) was incubated with (t-Boc)-NH2-PEG-NHS 
(Mw 2,000) in 2.5 mL DMSO for 2 h, and treated by TFA for deprotection 
of t-Boc. The folate-PEG conjugates (10 mg; 4 µmol) was incubated with 
Cy5.5-NHS (10 µmol) in 500 µL phosphate buffer (10 mM, pH 7.4) for 2 h 
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in the dark at room temperature. The final product, folate-PEG-Cy5.5 
conjugate was purified by HPLC.  
All cells were seeded onto 35 mm glass-bottom dishes at a density of 3 x 
104 cells in 2 mL of growth media with no sugar or pMPs (50 µM 
Ac3ManNAz). After 2 days of incubation, the cells were washed twice with 
DPBS (pH 7.4), and incubated with ADIBO-Cy5.5 (20 µM, final 
concentration) for 30 min at 37 °C for cellular imaging. The same method 
was applied to all cell lines: U87, MCF-7, MDA-MB-468, MDA-MB-436, 
KB, and A549 cells. 
For the comparative study using traditional biological binding molecules, 
all cells were seeded onto 35 mm glass-bottom dishes at a density of 3 x 104 
cells in 2 mL of growth media and grown to reach 60-80 % confluence. The 
cells were washed twice with DPBS (pH 7.4), and incubated with cRGD-
PEG-Cy5.5 (0.2 µM, final concentration), Cetuximab-Cy5.5 (0.1 µM, final 
concentration), or Folate-PEG-Cy5.5 (0.2 µM, final concentration) for 30 
min at 37 °C for cellular imaging. Fluorescence images were observed using 
confocal laser microscope (Leica TCS SP8, Leica Microsystems GmbH, 
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2.10 Flow cytometry analysis 
U87 cells were seeded onto 6-well plates at a density of 2 x 104 cells per 
well in 2 mL of media with no sugar or pMPs (50 µM Ac3ManNAz) treated 
with ADIBO-Cy5.5, as described previously. The cells were lifted with 
DPBS containing 2 % FBS (flow cytometry buffer) and washed twice in 
FACS buffer (1 mM EDTA). Twenty thousand cells per sample were 
performed by flow cytometry (BD FACSVerse, BD Biosciences, San Jose, 
CA, USA), and subsequent data analysis was analyzed using FlowJo 
software. 
 
2.11 In vivo/ex vivo imaging 
All experiments with live animals were performed in compliance with the 
laws and institutional guidelines of Korea Institute of Science and 
Technology (KIST) and approved by institutional committees. For in vivo 
and ex vivo experiments, U87 tumor cells (1.0 x 107 cells) were 
subcutaneously planted on flank of 5-week-old male athymic nude mice (20 
g, Orient, Gyeonggi-do, Korea). When the tumor reached about 100 mm2, 
the experiments were conducted. Cy5.5-labeled pMPs (40 mg 
Ac3ManNAz/kg) was injected intravenously once. The mice model was 
observed over 3 days to display in vivo biodistribution of pMPs. Near-
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infrared fluorescence (NIRF) images were observed using the IVIS Lumina 
K Series III in vivo imaging system (Perkin Elmer, Waltham, MA, USA). 
For analysis of expression of azide groups on tumor tissue, free 
Ac3ManNAz or pMPs (40 mg Ac3ManNAz/kg) were injected daily for 2 
days. After that, ADIBO-Cy5.5 (10 mM, 40 µL) was injected (n=3 per each 
experimental group). All the injections were done intravenously. The 
biodistribution and time-dependent tumor accumulation profiles were non-
invasively imaged by IVIS Lumina K Series III in vivo imaging system 
(Perkin Elmer, Waltham, MA, USA). All data were calculated by the region 
of interest (ROI) function of the IVIS molecular imaging software.  
The major organs and tumors were dissected from mice 72 hours post-
injection of Cy5.5-labeled pMPs. For analysis of expression of azide groups 
on tumor tissue, the tumors were dissected from mice 24 hours post-
injection of free Ac3ManNAz or pMPs (40 mg Ac3ManNAz). Ex vivo 
images were also obtained with a IVIS Lumina K Series III in vivo imaging 
system (Perkin Elmer, Waltham, MA, USA), and the fluorescence signal 
intensity at the ROI using IVIS molecular imaging software.  
 
2.12 Histological imaging 
For histological evaluation, the dissected tumor tissues were fixed in 4 % 
(v/v) buffered formalin solution, and embedded in optimum cutting 
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temperature (OCT) compound (Sakura, Tokyo, Japan) on dry ice. Sections 
were cut on a cryostat with 6 μm in thickness and picked up on slides with 
poly-D-lysine, dried at 45 °C under protection from light. Fluorescence of 
tumor tissue sections was observed (excitation: 673 nm, emission: 692 nm) 
by IX81-ZDC focus drift compensating microscope (Olympus, Tokyo, 
Japan). 
 
2.13 Western blot analysis of tumor tissues 
Preparation of U87 tumor-bearing mice models and intravenous injection 
of Ac3ManNAz (40 mg/kg) or pMPs (40 mg Ac3ManNAz/kg) were 
performed by the same method. 48 hours post-injection of Ac3ManNAz or 
pMPs, the major organs and tumors were dissected and transferred into 1 ml 
of lysis buffer (1 % SDS, 100 mM Tris∙HCl, pH 7.4) containing protease 
inhibitor cocktail (Complete, EDTA-free, Roche, NSW, Australia) and 
homogenized. The lysates were incubated at 4 ºC for 30 min, and insoluble 
debris was removed by centrifugation for 10 min at 3,000 x g. Using BCA 
protein assay kit, total soluble protein concentrations were measured. 
Staudinger reaction with phosphine-PEG3-biotin, SDS-PAGE, and western 
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2.14 Immunohistochemical analysis 
The dissected tumor tissues were retrieved from U87 tumor-bearing mice, 
and fixed in 4 % (v/v) buffered formalin solution. The tissues were 
dehydrated with a graded ethanol series, and embedded in paraffin. The 
paraffin tissues were sliced in 4 μm wide slices, and immunohistochemical 
staining was performed using phosphine-PEG3-biotin and streptavidin-HRP 
followed by the standard methods. The paraffin slices were dried and then 
mounted with Permount SP15-100 Toluene Solution (Fisher Scientific, NJ, 
USA) mounting media. The samples were observed by a light microscope 
(BX51, Olympus, Tokyo, Japan), and were photographed using a digital 
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3. RESULTS AND DISCUSSION 
 
3.1 Characterization of pMPs 
Poly (amido amine) (PAMAM) [G4] dendrimer is used as a basic 
structure of the polymerized metabolic precursors (pMPs) with a well-
established characteristics, and Ac3ManNAz is used for metabolic 
glycoengineering of sialic acids (Figure 1b). Ac3ManNAz can act as a 
building block in cell metabolism, since it can easily produce unnatural 
sialic acid, the most abundant glycan on tumor cell surface10. Conjugation of 
PAMAM [G4] dendrimer and Ac3ManNAz is completed by Steglich 
esterification mechanism (Figure 2). A completion of the reaction was 
determined by TLC (Figure 3). The free PAMAM [G4] dendrimer was 
stayed on the start line because of its high polarity, and pMPs was mobilized 
at maximum height on 3 days after the reaction. There is no further 
movement of pMPs after 3 days of reaction; the reaction time was fixed as 3 
days. After the reaction, free Ac3ManNAz, free PAMAM, and pMPs are 
analyzed by 1H NMR (Figure 4). By comparison of the reactants and 
product, 1H NMR peaks promised that the reaction was successfully 
completed. In addition, MALDI-TOF determined molecular weight of free 
PAMAM (m/z calculated: 20615, found: 19277) and that of pMPs (m/z 
calculated: 45447, found: 38599) (Figure 5). The Ac3ManNAz conjugation 
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efficiency was confirmed as 82.58 % using HPLC. Moreover, the size of 
pMPs was 3.88 ± 0.51 nm in aqueous condition as determined by dynamic 
light scattering (DLS). It promise that pMPs is small enough to freely move 
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Figure 4. 1H-NMR spectra of (a) PAMAM [G4], (b) Ac3ManNAz, and (c) 
PAMAM [G4]-Ac3ManNAz. 300 MHz NMR, solvent; DMSO-d6. 
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Figure 5. Matrix-assisted laser desorption/ionization-time of flight mass 
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3.2 In vitro studies of pMPs 
In vitro studies establish the generation of azide groups on the surface of 
tumor cells. First, azide group generation on cell surface was determined by 
cellular imaging and western blot analysis. Free Ac3ManNAz or pMPs was 
added to U87 tumor cells, and azide groups were determined by binding 
with ADIBO-Cy5.5 (red fluorescence). After treatment of free Ac3ManNAz 
or pMPs for 2 days, the viability of U87 cells was above 90% showing no 
significant cytotoxicity (Figure 6). ADIBO is chosen as a bioorthogonal 
chemical group functionalized with its high reactivity to azide groups via 
copper-free click chemistry5b. After treatment with ADIBO-Cy5.5, a higher 
fluorescence intensity of Cy5.5 was observed in both free Ac3ManNAz and 
pMPs treated U87 tumor cells than in untreated cells (Figure 7a). The 
microscopic images indicated that artificially introduced azide groups on the 
tumor cell surface were successfully generated by free Ac3ManNAz and 
pMPs, and effectively targeted by ADIBO-Cy5.5. Unlike U87 cells, a 
normal cell line, such as HDF (human dermal fibroblast) cell, did not show 
a strong signal of fluorescence after treatment of free Ac3ManNAz or pMPs 
(Figure 7c). As mentioned earlier, the surface of tumor cell is especially rich 
in sialic acid. Therefore, even though Ac3ManNAz can easily make 
unnatural sialic acid through metabolic glycoengineering, HDF normal cells 
cannot be visualized as U87 tumor cells. Western blot analysis using 
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phosphine-PEG3-biotin and streptavidin-HRP likewise demonstrated the 
generation of azide groups on tumor cells after the treatment of free 
Ac3ManNAz or pMPs (Figure 7b)11. Coomassie staining verifies that the 
total loading amount of proteins for each group of cell lysates is similar.  
 The heterogeneity of tumor cells complicates the circumstances for various 
subpopulations of tumor cells expressing different types and amounts of 
receptors9. Tumor is increasingly acknowledged as a combination of many 
disorders, each with varying causes, prognoses, and appropriate treatments. 
This diversity is recognizable not only across different types of tumor, but 
also within tumors of the same tissue. It is now known that cancer cells 
within the same tumor mass are heterogeneous in many aspects, including 
morphology or phenotypic expression, exhibition of inherent or acquired 
drug resistance, and capacity for initiating new tumor growth9. The 
heterogeneity and complexity of tumor is a huge obstruction of present drug 
delivery systems. However, our strategy can generate ‘receptor-like’ 
chemical groups on heterogeneous tumor cells by metabolic 
glycoengineering and overcome the limitation of current drug delivery 
systems. To demonstrate, a comparative study using representative click 
molecules and biological ligands was performed on various cell types: U87, 
MCF-7, MDA-MB-468, MDA-M-436, KB, and A549. ADIBO was used as 
a click molecule, and biological ligands such as cRGD (peptide), Cetuximab 
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(antibody), and folate were used, in order to label the azide group with 
Cy5.5 dye. The biological receptors for these ligands are known to be 
expressed in specific tumor cells, and each ligand labeled with Cy5.5 was 
bound to the targeted cells only as expected. However, after treatment of 
pMPs, all cell types (U87, MCF-7, MDA-MB-468, MDA-M-436, KB, and 
A549) were positively visualized on cellular imaging with ADIBO-Cy5.5 
(Figure 8a). The azide groups were generated on all cell types by metabolic 
glycoengineering, so they could bind with ADIBO-Cy5.5. The fluorescence 
intensity of these cells was quantified using flow cytometry analysis. 
Compared to the control cells with no treatment, the tumor cells treated with 
pMPs indicated a higher intensity (Figure 8b). These results show that azide 
groups are successfully generated from pMPs and formed on the surface of 
various cell lines. These results demonstrate that polymerized metabolic 
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Figure 7. Azide group generation on cell surface after treatment of pPMs. 
(a) Visualization of azide groups on the surface of U87 tumor cells after 
treatment of pMPs. (b) Coomassie staining and wetern blot analysis of U87 
tumor cells treated with pMPs. (c) Visualization of azide groups on the 
surface of human dermal fibroblasts (HDFs, normal cells) after treatment of 
pMPs.  
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Figure 8. Generation of azide groups by pMPs in various tumor cells. (a) 
The binding of click molecules and biological ligands to tumor cells. 
ADIBO-Cy5.5, cRGD-PEG-Cy5.5, Cetuximab-Cy5.5, and Folate-PEG-
Cy5.5 were visualized in red, yellow, green, and blue fluorescence (pseudo 
colors).  (b) Flow cytometry analysis of tumor cells after treatment of 
pMPs and ADIBO-Cy5.5. ADIBO-Cy5.5 was added to tumor cells treated 
with pMPs (50 μM) for 2 days. 
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3.3 In vivo studies of pMPs 
For in vivo studies, balb/c nude mice models bearing xenograft U87 
tumor on one side of flank are prepared. In vivo experiments start when the 
tumor size reached about 100 mm3. First, targetable glycans, unnatural sialic 
acids with azide groups, are artificially generated in target cancer cells by an 
intratumoral injection of the precursor, pMPs. Free Ac3ManNAz or pMPs 
were administered to each tumor model by intratumoral injection once a day 
for 3 days while saline was injected to the control mice model. The 
coomassie blue staining and western blot analysis of tumor tissues showed 
that the unnatural sialic acid with azide groups similarly with the cellular 
conditions (Figure 9). 
The biodistribution of pMPs is evaluated by time-dependent whole body 
imaging and ex vivo fluorescence analysis12. Whole body distribution was 
measured using a non-invasive IVIS Lumina K Series III in vivo imaging 
system in live animals. Cy5.5 labeled pMPs was intravenously injected once 
for fluorescent tracking. The images showed a slow excretion of pMPs over 
time (Figure 10a). Fluorescence intensities of tumor tissues from the images 
were quantified and plotted with a mild decreasing curve (Figure 10b). Total 
photon count in tumor site is distinctively higher in Cy5.5-labeled pMPs 
than free Cy5.5. Based on the EPR effect12, pMPs reached to the tumor 
more specifically and remained there using its characteristics of polymer. 
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Therefore, compared to small molecules like free Cy5.5 dye, pMPs bring a 
slower excretion through the whole body, especially from the tumor. In ex 
vivo fluorescence analysis of major organs and tumors, tumor tissue from 
mice pretreated with pMPs exhibited higher fluorescence intensity than 
other major organ tissues, except for the liver (Figure 10c and 10d). We 
expected that a strong signal from the liver was caused as a part of 
enterohepatic circulation.  
For intravenous injection of pMPs and metabolic glycoengineering on 
tumor tissue in vivo, western blot analysis, whole body and ex vivo 
fluorescence imaging were evaluated. Three different models of mice were 
prepared with saline, free Ac3ManNAz, or pMPs by intravenous injection. 
After 2 days of injection, ADIBO-Cy5.5 was also injected through tail vein 
to label the azide groups on cell surface by click chemistry. The tumors were 
collected and analyzed after all the injections. Compared to saline and free 
Ac3ManNAz, the tumor tissue from mice injected with pMPs revealed a 
strong band in western blot analysis (Figure 11a). The result showed that a 
large number of azide groups were generated on tumor tissue from pMPs by 
metabolic glycoengineering. The azide groups can be specifically generated 
in tumor tissue by pMPs because of its tumor-targeting ability via the EPR 
effect. The tumor tissue from mice pretreated with pMPs shows significantly 
more intense fluorescence in vivo images than tumor tissues pretreated with 
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saline or free Ac3ManNAz (Figure 11b). Even though the number of azide 
groups generated by Ac3ManNAz and pMPs were similar in vitro, the in 
vivo images were different because free Ac3ManNAz is a small molecule 
that has no tumor-targeting ability. The tumors from each group were 
dissected after 24 hours from injection of ADIBO-Cy5.5. They were 
analyzed by ex vivo fluorescence images and tumor tissue from mice 
pretreated with pMPs showed distinctively higher intensity of fluorescence 
than tumors from other group pretreated with saline or free Ac3ManNAz 
(Figure 11c and 11d). Furthermore, immuohistological staining supports the 
metabolic glycoengineering of pMPs. The dark brown spots which show the 
expression of azide group are intense in tumor tissue, compared to other 
organ tissues (Figure 12). The immunohistology also demonstrates that 
metabolic glycoengineering can specifically occur on the tumor tissue after 
intravenous injection of pMPs. A large number of azide groups can be 
successfully generated on tumor tissue in vivo. More specifically, 
histological evaluation proves the generation of azide group from pMPs by 
the accumulation of ADIBO-Cy5.5 in tumor tissue (Figure 13). It was 
significantly higher in pMPs pretreated mice group than other groups with 













Figure 9. Intratumoral injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. Coomassie staining and wetern blot analysis of 













Figure 10. Biodistribution of pMPs in tumor-bearing mice. (a) Whole body 
images of mice after intravenous injection of Cy5.5-labeled pMPs. (b) 
Fluorescence intensities of tumor tissues from (a). (c) Ex vivo fluorescence 
images of major organs and tumor from 72 h post-injection of pMPs. (d) 
Fluorescence intensities of major organs and tumor tissue from (c). 
 
  







Figure 11. Intravenous injection of pMPs and metabolic glycoengineering 
on tumor tissue in vivo. (a) Coomassie staining and wetern blot analysis of 
tumor tissues after intravenous injection of saline, free Ac3ManNaz, or 
pMPs. (b) Whole body images of mice after intraveneous injection of 
ADIBO-Cy5.5, pretreated with pMPs. (c) Ex vivo fluorescence images of 
tumors from each group 24 h postinjection of ADIBO-Cy5.5. (d) 
Fluorescence intensities of tumor tissues from (c). 
  





Figure 12. Intravenous injection of saline, free Ac3ManNAz, and pMPs and 
metabolic glycoengineering on tumor tissue in vivo. Histological staining of 
major organs and tumor tissues after intravenous injection of saline (left 
panel), free Ac3ManNAz (middle panel), and pMPs (right panel). 
 
  








Figure 13. Fluorescence images of tumor tissues after intravenous injection 
of ADIBO-Cy5.5 to tumor-bearing mice pretreated with saline (top panel), 
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4. CONCLUSION 
  
In this study, we have designed polymerized metabolic precursors (pMPs) 
to overcome tumor heterogeneity via metabolic glycoengineering and click 
chemistry. PAMAM [G4] dendrimers are conjugated with Ac3ManNAz to 
produce pMPs. The intravenously injected pMPs reach to the tumor cell 
specifically by EPR effect and successfully produce azide groups on the 
surface of tumor cells. In particular, an expression of azide groups enables a 
generation of ‘receptor-like’ chemical reporters from pMPs itself. 
Furthermore, by using AIBO-Cy5.5, these azide reporters in the tumor tissue 
can be labeled via copper-free click chemistry in vivo condition. Thus, the 
tumor can be specifically visualized by optical imaging system. Our results 
suggest a new targeting strategy which can overcome tumor heterogeneity 
using site-specific metabolic glycoengineering and copper-free click 
chemistry. Since the whole procedure is conducted of intravenous injections 
only, allowing it to be applied to tumor diagnosis and therapy even when the 
location of the tumor tissue is not well defined. Our strategy significantly 
demonstrates that it may have a great potential for further biomedical 
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요약문 
 
기존에 암 치료는 항암제를 단독으로 직접 투여하는 방식을 
사용하였다. 하지만 이러한 방법은 암 세포 뿐만 아니라 정상 
세포까지 독성을 야기하는 등 다양한 부작용을 나타내었다. 
이러한 문제점을 해결하기 위해서 항암제를 표적 암 세포에 
전달하는 다양한 나노기술이 개발되어왔다. 본 연구에서는 
고분자화 대사 전구체를 이용하여 암 표적화 능력을 향상 시키는 
방법에 대한 것이다. 또한, 암 세포가 갖는 고유 수용체의 양적 
제한에서 비롯된 표적 능력의 한계 및 암 이질성을 극복할 수 
있는 방법에 대한 것이다. 이 방법은 대사 당쇄 조작과 무동 클릭 
화학을 이용하였다. PAMAM [G4] 덴드리머와 Triacetylated 
N-azidoacetyl-D-mannosamine (Ac3ManNAz)의 화학적 
결합을 이용하여 암 조직에 특이적으로 인공 표적 수용체인 
azide 기를 도입시키는 방법이며, 이 방법을 이용하면 이질성을 
갖는 암 세포들을 단일화된 표현 형질로 바꿀 수 있다. 또한 
이렇게 도입된 인공 표적 수용체를 표적으로 하는 클릭 화학을 
이용하면 암 표적화 능력을 향상 시킬 수 있다. 본 연구에서 개발 
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된 고분자화 대사 전구체를 이용한 암 표적화 능력 향상 방법을 
이용하면 이질성을 갖는 암의 종류에 상관없이 표적 능력을 높일 
수 있을 것으로 예상된다.  
 
주요 어: 고분자화 대사 전구체, 종양 이질성, 물질 대사 당공학, 
클릭 화학, 광학 이미징  
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